title: Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
abstract: Cytomegalovirus (CMV) infection is a major complication following solid organ transplantation resulting in significant morbidity and mortality. The guidelines published in 2004 have recommendations for therapy; however, the frequency of resistant CMV infection is increasing and therapy is not clearly defined. There are a few alternatives to ganciclovir such as foscarnet, cidofovir, and leflunomide; however, their use is limited by adverse effects. This report summarizes the successful use of high-dose ganciclovir for the treatment of a resistant CMV caused by UL97 mutation.
authors.affiliation: Transplant Center, Chicago, Illinois 60612, USA.
authors.forename: P
authors.initials: P
authors.lastname: West
authors.forename: M
authors.initials: M
authors.lastname: Schmiedeskamp
authors.forename: H
authors.initials: H
authors.lastname: Neeley
authors.forename: J
authors.initials: J
authors.lastname: Oberholzer
authors.forename: E
authors.initials: E
authors.lastname: Benedetti
authors.forename: B
authors.initials: B
authors.lastname: Kaplan
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D024882:Drug Resistance, Viral / Q000235:genetics; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009154:Mutation; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D017853:Phosphotransferases (Alcohol Group Acceptor); C075365:ganciclovir kinase; D015774:Ganciclovir